Imagine you're editing a résumé. A single-pass rewrite might fix grammar but miss the hiring manager's actual priorities. Now imagine a coach sitting beside you: after each draft, they tell you which sections improved, which regressed, and how far you've drifted from the original structure. Over three or four rounds, your résumé converges on something that satisfies multiple constraints simultaneously. That's the core mechanism here — except the résumé is a drug-like molecule, the constraints are biological properties (activity, solubility, toxicity), and the coach is a feedback vector encoding how much each property improved and how structurally similar the new molecule remains to the starting point. The committed claim: an LLM explicitly trained via reinforcement learning to use multi-turn feedback achieves higher multi-objective molecular optimization success rates than the same LLM operating in single-turn mode. The paper builds atop GeLLM³O, a recent state-of-the-art LLM for multi-objective mol-opt, and wraps it in a framework called MFG (Multi-turn Feedback Guided). The key architectural addition is a feedback vector — a compact numerical summary of property deltas and Tanimoto similarity from the previous turn — concatenated to the prompt at each step. A feedback-aligned reward function then scores the LLM's output based on progressive improvement, not just absolute quality. Training uses RL (the paper doesn't specify PPO vs. DPO vs. another variant in the abstract, which is a gap) to align the model with this iterative reward signal. On the ladder: GeLLM³O-MFG hits an average similarity-constrained success rate of 81.50% across ten multi-objective tasks, compared to 70.81% for the base GeLLM³O. That's a meaningful 10.69 percentage-point lift — roughly 15% relative improvement. The baseline is current and named, which is good practice. What's missing from this abstract is comparison against non-LLM baselines: genetic algorithms, reinforcement learning from scratch on molecular graphs (e.g., REINVENT, MolDQN), or classical matched molecular pair approaches. If classical methods already clear 85% on these tasks, the headline number matters less. The integrity profile has clear strengths and gaps. The comparison to GeLLM³O is apples-to-apples — same base model, same tasks, ablation is clean. Ten tasks is a reasonable breadth. But the abstract doesn't mention held-out test sets versus training-distribution tasks, doesn't reference code availability, and doesn't address whether the ten tasks were selected before or after tuning. The feedback vector design introduces a degree of freedom: how the property improvements and similarity are weighted could be tuned to favor the benchmark. Without ablations on the feedback vector composition (which may exist in the full paper), this is a soft spot. The milestone question is concrete but the paper doesn't push it far enough. Success rate went from 71% to 82% — what gets you to 95%? In drug discovery, the real gate is not computational success rate but whether optimized molecules survive experimental validation. The gap between in-silico success and wet-lab confirmation is where most mol-opt papers quietly deflate. The honest next milestone is: does MFG's multi-turn optimization produce molecules that a medicinal chemist would actually synthesize and test? That's a lab experiment, not a compute experiment. The obvious successor experiment is scaling the number of turns and measuring diminishing returns. The abstract describes multi-turn optimization but doesn't report turn-by-turn success curves. How much of the 11-point gain comes from turn 2 versus turn 5? If most of the lift is in the first additional turn, the multi-turn framing is less interesting than a simple "revise once" approach. My read: the authors likely have this data and are either saving it for the full paper's figures or found that gains plateau quickly after 2-3 turns, which would be worth reporting honestly. The broader field fight here is whether LLMs are the right backbone for molecular optimization at all, versus graph neural networks or evolutionary methods that operate natively on molecular structure. MFG's contribution is real but incremental: it demonstrates that feedback-conditioned RL training helps LLMs iterate, which is a useful engineering insight. It does not settle whether LLMs should be the tool of choice. The 81.5% number needs context against the full landscape of mol-opt methods before anyone changes their pipeline.
